Hegi ME - Search Results

1

Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes.

Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I, Nozaki M, Diserens AC, Hamou MF, Dietrich PY, Regli L, Janzer RC, Bucher P, Stupp R, de Tribolet N, Domany E, Hegi ME. Godard S, et al. Among authors: hegi me. Cancer Res. 2003 Oct 15;63(20):6613-25. Cancer Res. 2003. PMID: 14583454

2

p53 transdominance but no gain of function in mouse brain tumor model.

Hegi ME, Klein MA, Rüedi D, Chène P, Hamou MF, Aguzzi A. Hegi ME, et al. Cancer Res. 2000 Jun 1;60(11):3019-24. Cancer Res. 2000. PMID: 10850451

3

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.

Fulci G, Labuhn M, Maier D, Lachat Y, Hausmann O, Hegi ME, Janzer RC, Merlo A, Van Meir EG. Fulci G, et al. Among authors: hegi me. Oncogene. 2000 Aug 3;19(33):3816-22. doi: 10.1038/sj.onc.1203700. Oncogene. 2000. PMID: 10949938

4

Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.

Klein MA, Rüedi D, Nozaki M, Dell EW, Diserens AC, Seelentag W, Janzer RC, Aguzzi A, Hegi ME. Klein MA, et al. Among authors: hegi me. Oncogene. 2000 Nov 9;19(47):5329-37. doi: 10.1038/sj.onc.1203941. Oncogene. 2000. PMID: 11103934

5

p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.

Nozaki M, Tada M, Kashiwazaki H, Hamou MF, Diserens AC, Shinohe Y, Sawamura Y, Iwasaki Y, de Tribolet N, Hegi ME. Nozaki M, et al. Among authors: hegi me. Brain Pathol. 2001 Jul;11(3):296-305. doi: 10.1111/j.1750-3639.2001.tb00400.x. Brain Pathol. 2001. PMID: 11414472 Free PMC article.

6

Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1.

Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, Hamou MF, Fairlie DW, Breit SN, Paralkar VM, de Tribolet N, Van Meir EG, Hegi ME. Albertoni M, et al. Among authors: hegi me. Oncogene. 2002 Jun 20;21(27):4212-9. doi: 10.1038/sj.onc.1205610. Oncogene. 2002. PMID: 12082608

7

Prognostic factors for low-grade gliomas.

Stupp R, Janzer RC, Hegi ME, Villemure JG, Mirimanoff RO. Stupp R, et al. Among authors: hegi me. Semin Oncol. 2003 Dec;30(6 Suppl 19):23-8. doi: 10.1053/j.seminoncol.2003.11.029. Semin Oncol. 2003. PMID: 14765381 Review.

8

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.

Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, Van Melle G, de Tribolet N, Stupp R. Hegi ME, et al. Clin Cancer Res. 2004 Mar 15;10(6):1871-4. doi: 10.1158/1078-0432.ccr-03-0384. Clin Cancer Res. 2004. PMID: 15041700 Clinical Trial.

9

INK4a/Arf is required for suppression of EGFR/DeltaEGFR(2-7)-dependent ERK activation in mouse astrocytes and glioma.

Lachat Y, Diserens AC, Nozaki M, Kobayashi H, Hamou MF, Godard S, De Tribolet N, Hegi ME. Lachat Y, et al. Among authors: hegi me. Oncogene. 2004 Sep 9;23(41):6854-63. doi: 10.1038/sj.onc.1207872. Oncogene. 2004. PMID: 15273738

10

Growth promoting signaling by tenascin-C [corrected].

Ruiz C, Huang W, Hegi ME, Lange K, Hamou MF, Fluri E, Oakeley EJ, Chiquet-Ehrismann R, Orend G. Ruiz C, et al. Among authors: hegi me. Cancer Res. 2004 Oct 15;64(20):7377-85. doi: 10.1158/0008-5472.CAN-04-1234. Cancer Res. 2004. PMID: 15492259

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

156 results

Search Page

Filters